[
  {
    "ts": "2025-05-27T11:00:00+00:00",
    "headline": "Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF",
    "summary": "Rein Therapeutics (\"Rein\") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.",
    "url": "https://finance.yahoo.com/news/rein-therapeutics-announces-first-patient-110000006.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "90448e9d-f8f5-3735-b498-0195273238e0",
      "content": {
        "id": "90448e9d-f8f5-3735-b498-0195273238e0",
        "contentType": "STORY",
        "title": "Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF",
        "description": "",
        "summary": "Rein Therapeutics (\"Rein\") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.",
        "pubDate": "2025-05-27T11:00:00Z",
        "displayTime": "2025-05-27T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9",
          "originalWidth": 400,
          "originalHeight": 226,
          "caption": "Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GC9xRf4_4ihLLD4tMxxSag--~B/aD0yMjY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9.cf.webp",
              "width": 400,
              "height": 226,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiyHlQOyPNMB_ai43FEmJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rein-therapeutics-announces-first-patient-110000006.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rein-therapeutics-announces-first-patient-110000006.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RNTX"
            },
            {
              "symbol": "IQV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]